Fuzzy....I completely agree: "RVX was & still is considered a very high risk/volitile stock"

Yes, that is the space we are in. Obviously anyone investing in a development stage biotech should know the risks, there's no earnings and companies in this space burn cash. You're looking for 2 things.....positive trial results, and ultimately either regulatory approval based on those results and/or a buyout. But while you're looking for those things you have to be aware that they might not happen....if a trial fails, we all know what happened after Assure.

Its like heading out to do some ice fishing. Sure you want to catch some fish, that's the goal. But first you have to be prepared to head out on the lake, you have to dig the hole....and then after all is said and done, there's no promise the fish will bite....and of course your feet are gonna get cold, even in a heated little hut....make sure ya got a couple pairs of wool socks on.

With all that being said, looking at the past year....the fishing has been pretty good, especially compared with other stocks in this exact same space. Sure, some have done better....many worse. But RVX hasn't been the roller coaster that a lot of biotechs have been over the past 12 months....the ride up last spring was wild, but the drift down was prety steady.